Hypertension Pharmacology Guideline Summary

ACE INHIBITORS

• Absolute contraindications – history of angio‑edema, pregnancy, bilateral renal‑artery stenosis, hyper‑kalemia, and severe renal impairment. Bilateral renal‑artery stenosis is contraindicated because ACE‑inhibition dilates the efferent arteriole, markedly lowering glomerular filtration pressure and precipitating acute renal failure. 1
• Creatinine rise after initiation – a ≤30 % increase in serum creatinine within the first 2 weeks reflects reduced efferent‑arteriole resistance and is expected; larger rises warrant evaluation. 1
• Cough mechanism – ACE inhibition prevents conversion of angiotensin I to II and blocks degradation of bradykinin; accumulated bradykinin stimulates airway sensory nerves, producing a dry cough. 1

ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

• Cough incidence – ARBs do not inhibit bradykinin breakdown, so they rarely cause cough. 1
• Combination with ACE‑inhibitor – Adding an ARB to an ACE‑inhibitor provides no additional BP benefit and increases risks of hyper‑kalemia, acute kidney injury, and hypotension (e.g., ONTARGET trial). [2][3]

THIAZIDE‑LIKE DIURETICS

• Hyperuricemia mechanism – Thiazides compete with uric acid for organic‑anion transporters in the proximal tubule, reducing uric‑acid secretion and raising serum urate levels, which can precipitate gout attacks. 1

CALCIUM‑CHANNEL BLOCKERS (DIHYDROPYRIDINES)

• Peripheral edema – Dihydropyridine CCBs cause arteriolar dilation → ↑ capillary hydrostatic pressure → fluid extravasation into interstitium; loop or thiazide diuretics do not counteract this because the edema is not volume‑dependent. 2
• Acute MI contraindication – Immediate‑release nifedipine causes reflex tachycardia and increased myocardial oxygen demand, worsening ischemia; a slow‑release formulation or alternative agents (e.g., amlodipine) are safer. [1][4]
• Edema mitigation – Co‑administration of an ACE‑inhibitor reduces CCB‑induced edema by decreasing post‑capillary venous pressure via afterload reduction. 2

POTASSIUM‑SPARING DIURETICS

• Fourth‑line agent for resistant hypertension – Add a mineralocorticoid receptor antagonist (spironolactone) at 25 mg daily; monitor serum potassium and renal function. [1][5]
• Gynecomastia with spironolactone – Caused by blockade of androgen receptors in breast tissue; eplerenone provides similar aldosterone antagonism with minimal anti‑androgen effect. [1][4]
• eGFR threshold – Initiation of spironolactone is contraindicated when eGFR < 30 mL/min/1.73 m²; the primary safety concern is hyper‑kalemia. 5

ALPHA‑2 AGONISTS

• Clonidine mechanism – Stimulates central α₂‑adrenergic receptors in the nucleus tractus solitarius, decreasing sympathetic outflow and increasing parasympathetic tone, which lowers heart rate and peripheral vascular resistance. [1][2]4
• Abrupt discontinuation – Leads to rebound sympathetic surge → severe hypertension and tachycardia; tapering over 1–2 weeks prevents this. [1][2]4
• Adverse effects – Dry mouth, sedation, constipation, rebound hypertension, and bradycardia, all stemming from central α₂‑receptor activation. [1][2]4
• Pregnancy first‑line – Methyldopa is the preferred α₂‑agonist in pregnancy, typically dosed 250–500 mg 2–3 times daily. [1][4]

BETA BLOCKERS

• First‑line status – Not recommended as initial therapy for uncomplicated hypertension in adults ≥ 60 years (Class III, Level B). 6
• Preferred indications – Heart failure with reduced ejection fraction, post‑myocardial infarction, and chronic stable angina. [1][4]7
• Nebivolol – Combines β₁‑blockade with endothelial nitric‑oxide release, providing vasodilation beyond traditional β‑blockers. [1][4]
• Mortality‑benefit β‑blockers in HFrEF – Carvedilol, metoprolol succinate, and bisoprolol are proven to improve survival and are preferred over other β‑blockers. [1][4]7

DIRECT VASODILATORS

• Hydralazine compensations – Reflex tachycardia via baroreceptor‑mediated sympathetic activation; sodium‑water retention from secondary activation of the renin‑angiotensin‑aldosterone system. Always co‑prescribed with a β‑blocker and a diuretic. [1][2]4
• Hydralazine‑induced lupus – Dose‑related (≥ 100 mg/day) development of a lupus‑like syndrome with arthralgia, fever, and positive ANA. [1][4]
• Minoxidil requirements – Needs a loop diuretic to counteract marked fluid retention; unique adverse effects include hypertrichosis and pericardial effusion. [1][4]

COMBINATION THERAPY & TREATMENT ALGORITHMS

• Initial therapy for stage 2 hypertension with ASCVD risk ≥ 15 % – Start with a two‑drug fixed‑dose combination (ACE‑I/ARB + CCB or ACE‑I/ARB + thiazide‑like diuretic). [1][5]3
• Resistant hypertension pathway – After maximally tolerated doses of ACE‑I/ARB, CCB, and thiazide‑like diuretic, add spironolactone; screen for secondary causes, medication adherence, and assess electrolytes. 5
• Dual RAS blockade contraindication – Combining ACE‑I and ARB increases risk of hyper‑kalemia, acute kidney injury, and hypotension without additional cardiovascular benefit. [2][3]
• Beta‑blocker + CCB selection – When a CCB is added to a β‑blocker, choose a dihydropyridine (e.g., amlodipine); avoid non‑dihydropyridines (verapamil, diltiazem) because of additive negative inotropic and AV‑node effects. [2][3]
• Three‑drug regimen for diabetic CKD (eGFR ≈ 55 mL/min, proteinuria ≈ 300 mg/day) – 1) ACE‑I (renin‑angiotensin blockade for proteinuria), 2) amlodipine (CCB, effective in African‑American patients and low‑renin states), 3) chlorthalidone (thiazide‑like diuretic for volume control). Supported by ACC/AHA 2025 recommendations. [1][7]

HYPERTENSIVE URGENCY & EMERGENCY

• Definitions – Urgency: SBP ≥ 180 mmHg or DBP ≥ 110 mmHg without acute target‑organ damage. Emergency: Same BP thresholds with evidence of end‑organ injury. 1
• Oral agents for urgency – Captopril (ACE‑I), oral labetalol (β‑blocker + α‑blocker), and clonidine (central α₂‑agonist); all act rapidly to lower BP. 1
• IV agent for hypertensive emergency with ACS – Intravenous nitroglycerin is first‑line because it reduces preload and myocardial oxygen demand while providing rapid BP control. 1
• Target BP reduction in first hour – Lower MAP by 10–15 % (or SBP to < 160 mmHg); avoid > 25 % reduction to prevent cerebral or coronary hypoperfusion. 1
• Contraindicated IV in heart failure – Sodium nitroprusside is avoided in overt heart failure due to risk of profound hypotension and cyanide toxicity. 1

SPECIAL POPULATIONS & CONTRAINDICATIONS

• Pregnancy antihypertensives – Preferred oral agents: labetalol, methyldopa, and nifedipine; IV hydralazine is the drug of choice for hypertensive emergencies in pregnancy. [1][4]
• ACE‑I in bilateral renal‑artery stenosis – Leads to abrupt fall in GFR because efferent‑arteriole dilation removes the compensatory pressure needed for filtration; can cause acute renal failure. [1][2]4
• Asthma – Non‑selective β‑blockers are contraindicated due to bronchoconstriction; cardio‑selective β₁‑blockers (e.g., metoprolol) are relatively safer if needed. [1][4]8

MONITORING & ADVERSE EFFECTS

• Hyper‑kalemia with ACE‑I + spironolactone – Both drugs suppress aldosterone, reducing renal potassium excretion; management includes potassium‑lowering agents (e.g., patiromer) and dose adjustment. 1

Optimizing Antihypertensive Therapy: Evidence‑Based Sequencing of Agents

1. Foundation Regimen for Hypertension

• The 2018 American Heart Association (AHA) Resistant Hypertension guideline recommends a three‑drug foundation of a renin‑angiotensin system (RAS) blocker, a calcium‑channel blocker (CCB), and a thiazide‑type diuretic at maximal or maximally tolerated doses before labeling a patient as resistant. [@1][@4]
• ACC/AHA guidelines assign Grade A evidence to the combination of an ACE inhibitor (or ARB) + CCB for dual therapy, showing superior blood‑pressure reduction and cardiovascular outcomes compared with other dual combinations. [@2][@5]

2. Calcium‑Channel Blockers as the Third Agent

• Adding a long‑acting dihydropyridine CCB (amlodipine 2.5–10 mg daily) completes the optimal three‑drug regimen when a patient is already on an ACE inhibitor and a beta‑blocker. [@1][@2][@3]
• Dihydropyridine CCBs (amlodipine, felodipine, nifedipine LA) are preferred because they provide complementary vasodilation without the bradycardia risk associated with non‑dihydropyridines. [@2][@3]
• Initiate amlodipine at 2.5–5 mg once daily and titrate to 10 mg as tolerated; the drug offers once‑daily dosing with consistent 24‑hour blood‑pressure control. [@2][@3]
• Amlodipine is the most extensively studied long‑acting dihydropyridine CCB and has demonstrated proven cardiovascular outcome benefits. [@2]

3. Thiazide‑Like Diuretics as the Fourth Agent (if needed)

• If blood pressure remains uncontrolled after ACE inhibitor + beta‑blocker + CCB, add a thiazide‑like diuretic (chlorthalidone 12.5–25 mg daily or indapamide 1.25–2.5 mg daily). [@1][@4]
• Chlorthalidone is preferred over hydrochlorothiazide because of its longer half‑life and superior cardiovascular outcome data from clinical trials. [@1][@2]
• Thiazide‑like diuretics are more potent and longer‑acting than traditional thiazides, enhancing BP control. [@1]

4. Management of Resistant Hypertension (BP ≥ 130/80 mmHg on four agents)

4.1 Optimize Diuretic Therapy

• Substitute chlorthalidone or indapamide if a less effective thiazide is being used. [@1][@4]

4.2 Add a Mineralocorticoid Receptor Antagonist (MRA)

• Add spironolactone 25–50 mg daily or eplerenone 50–100 mg daily (provided eGFR ≥ 45 mL/min/1.73 m²). [@1][@3][@6]
• Spironolactone is the most effective fourth‑line agent for resistant hypertension (Grade A evidence). [@1][@4]
• Monitor serum potassium and renal function closely when an MRA is combined with an ACE inhibitor. [@1][@3]
• Eplerenone has a lower risk of hormonal side effects (e.g., gynecomastia) but may require twice‑daily dosing. [@3][@7]

4.3 Additional Fourth‑Line Agents (if BP remains uncontrolled)

• Hydralazine 25 mg three times daily, titrated upward as needed. [@1][@4]
• Minoxidil 2.5 mg 2–3 times daily, always paired with a beta‑blocker and a loop diuretic to counteract reflex tachycardia and fluid retention. [@1][@4]
• Refer the patient to a hypertension specialist if target BP is not achieved after six months of optimized therapy. [@6]

5. Special Considerations

5.1 Beta‑Blocker Use

• Beta‑blockers are not first‑line for uncomplicated hypertension in patients ≥ 60 years (per Canadian Cardiovascular Society guidance). [@8][@5]

5.2 CCB‑Related Edema

• Dose‑related pedal edema is a common adverse effect of CCBs, especially in women; the edema results from preferential arteriolar vasodilation and does not respond to diuretics. [@2][@3]
• Combining an ACE inhibitor with a CCB can attenuate CCB‑induced edema compared with CCB monotherapy. [@2]

5.3 Drug‑Interaction cautions

• Avoid ACE inhibitor + ARB combination due to increased risk of hyperkalemia, hypotension, and renal dysfunction without added benefit. [@8][@5]
• Use caution when pairing non‑dihydropyridine CCBs (diltiazem, verapamil) with beta‑blockers because of heightened bradycardia and heart‑block risk. [@2][@8]

6. Evaluation for Secondary Hypertension (before escalating therapy)

• Screen for obstructive sleep apnea, primary aldosteronism (especially if hypokalemia is present), and renal artery stenosis. [@6][@7]
• Assess medication adherence and consider white‑coat effect; confirm with home or ambulatory blood‑pressure monitoring. [@1][@4][@6]

Management of Inadequate Blood Pressure Control with Hyperkalemia in CKD Stage 3

Immediate Hyperkalemia Management

• Serum potassium ≥ 5.5 mmol/L must be actively lowered before initiating any renin‑angiotensin system (RAS) blocker, because uncontrolled hyperkalemia increases the risk of cardiac events. KDIGO 2021 recommends this precaution (Grade 1B). 9, 10
• KDIGO 2021 advises that hyperkalemia caused by RAS inhibitors should first be addressed with potassium‑lowering measures rather than discontinuing the RAS blocker. (Grade 1B) 9

Potassium‑Lowering Therapies

• Initiate a novel potassium binder—patiromer (starting 8.4 g twice daily) or sodium zirconium cyclosilicate (SZC) (10 g three times daily for 48 h, then 5–10 g once daily)—to achieve normokalemia and enable future RAS‑inhibitor therapy. (Evidence from phase III trials) 10
• Patiromer and SZC are superior to sodium polystyrene sulfonate (SPS) in both efficacy and safety, with SPS linked to severe gastrointestinal adverse events and limited chronic‑use data. (Level A) 10
• In the AMBER trial, patiromer allowed 86 % of participants to remain on spironolactone versus 66 % on placebo (P < 0.0001), demonstrating that potassium binders facilitate continuation of cardioprotective medications. (Grade A) 10
• Patiromer must be taken ≥3 hours apart from other oral drugs to avoid binding interactions; SZC has no such restriction. (Pharmacologic guidance) 10

Antihypertensive Sequencing in CKD Stage 3 (eGFR ≈ 40 mL/min/1.73 m²)

Why Not Add a RAS Inhibitor First

• Adding an ACE inhibitor or ARB at this eGFR with potassium 5.5 mmol/L carries a 30–50 % risk of further potassium elevation, potentially worsening hyperkalemia. (Observational data) 11, 9
• KDIGO 2021 recommends checking serum potassium 2–4 weeks after RAS‑inhibitor initiation and reducing the dose or stopping the agent if potassium exceeds 5.5 mmol/L despite medical therapy. (Grade 1B) 9
• RAS‑inhibitor initiation should be deferred until potassium is consistently < 5.0 mmol/L on a potassium binder. (Clinical pathway) 9

Amlodipine as the Evidence‑Based Third Agent

• Amlodipine 5–10 mg once daily is the preferred long‑acting dihydropyridine CCB because ACC/AHA 2018 assigns Grade A evidence to a CCB + RAS‑inhibitor combination for dual therapy. (Guideline grade) 11
• Amlodipine does not exacerbate hyperkalemia, making it the safest add‑on when hyperkalemia is present. (Safety data) 11, 9
• Initiate amlodipine at 2.5–5 mg daily and titrate to 10 mg as tolerated; dose‑related pedal edema occurs in up to 10 % of patients (more common in women) and is generally unresponsive to diuretics. (Adverse‑event profile) 11

Diuretic Selection

• Loop diuretics (e.g., furosemide 20–80 mg twice daily, torsemide 5–10 mg once daily, bumetanide 0.5–2 mg twice daily) are preferred over thiazides when eGFR < 30 mL/min/1.73 m² because thiazides lose efficacy at lower GFR. (Pharmacologic rationale) 11
• At eGFR ≈ 40 mL/min/1.73 m², either a thiazide‑like diuretic (chlorthalidone 12.5–25 mg once daily) or a loop diuretic may be used; loops provide more reliable kaliuresis to counteract hyperkalemia. (Therapeutic option) 11

RAS‑Inhibitor Initiation (After Potassium Stabilization)

• Once potassium is < 5.0 mmol/L on a binder and amlodipine is at target dose, add an ACE inhibitor (e.g., lisinopril 10–40 mg once daily) or an ARB (e.g., losartan 50–100 mg once daily). (Stepwise escalation) 11, 9
• KDIGO 2021 strongly recommends RAS inhibitors for CKD patients with albuminuria (Grade 1B), provided potassium remains stable. (Guideline recommendation) 9
• Check potassium and creatinine 2–4 weeks after RAS‑inhibitor initiation; a rise in serum creatinine ≤30 % is acceptable as a hemodynamic effect. (Monitoring guidance) 9
• If potassium rises above 5.5 mmol/L after RAS initiation, increase the potassium‑binder dose rather than discontinuing the RAS inhibitor. (Management algorithm) 9

Safety Considerations

Avoid Dual RAS Blockade

• Combining an ACE inhibitor with an ARB should never be done; the ONTARGET trial demonstrated higher rates of hyperkalemia, acute kidney injury, and hypotension without added cardiovascular benefit. (Level A evidence) 11, 9

Mineralocorticoid Receptor Antagonists (MRAs)

• MRAs (e.g., spironolactone) are contraindicated when eGFR < 45 mL/min/1.73 m² because of prohibitive hyperkalemia risk. (Safety guideline) 11
• KDIGO 2021 notes that MRAs may cause hyperkalemia or reversible declines in kidney function, especially in low‑eGFR patients. (Grade 1B) 9

Long‑Term Monitoring Schedule

Blood Pressure Monitoring After Antihypertensive Regimen Changes

Target Blood Pressure Goals

• Home blood‑pressure monitoring should verify that systolic/diastolic values remain below 130/80 mm Hg, which is the target recommended by the American College of Cardiology/American Heart Association (ACC/AHA) 2018 hypertension guideline after any adjustment of antihypertensive therapy. 12